Entrectinib for the treatment of patients with ROS1-positive, advanced non-small-cell lung cancer (NSCLC) not previously treated with ROS-1 inhibitors
Scottish Medicines Consortium
Record ID 32018000972
English
Authors' objectives:
To assess clinical and cost effectiveness.
Details
Project Status:
Completed
URL for project:
https://www.scottishmedicines.org.uk/medicines-advice/entrectinib-rozlytrek-full-smc2294/
Year Published:
2021
URL for published report:
https://www.scottishmedicines.org.uk/medicines-advice/entrectinib-rozlytrek-full-smc2294/
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
Scotland, United Kingdom
MeSH Terms
- Carcinoma, Non-Small-Cell Lung
- Antineoplastic Agents
- Lung Neoplasms
- Protein Kinase Inhibitors
Contact
Organisation Name:
Scottish Medicines Consortium (SMC)
Contact Address:
Delta House | 50 West Nile Street
Contact Name:
Susan Downie
Contact Email:
susan.downie3@nhs.scot
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.